Beyond weight management, retatrutide shows promise for liver fat reduction, glycemic control in type 2 diabetes, and potentially cardiovascular risk reduction
Nicole Burton, in Liberty, Kentucky, has lost about 120 pounds since she went on a GLP-1 in May 2024
While tirzepatide therapy has already earned FDA approval and demonstrated impressive results in landmark clinical trials, retatrutide has generated considerable excitement as a next-generation triple agonist with the potential to push weight loss outcomes even further
Reference: Chubb, B., Gupta, P., Gupta, J., Nuhoho, S., Kallenbach, K., & Orme, M
Danita Berry a year ago Now this is the pharmacy that needs to be on every corner
0.1 mM EDTA